June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
24-2 Visual Field Progression Rates Better Correlate with GCL than RNFL Rate of Change in Glaucoma
Xin Xin Xing; Ari Leshno; Emmanouil Tsamis; Aakriti Garg Shukla; Qing Wang; Noga Harizman; George A Cioffi; Sitara Hanif Hirji; C. Gustavo De Moraes; Jeffrey M Liebmann
Author Affiliations & Notes
  • Xin Xin Xing
    Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States
  • Ari Leshno
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Emmanouil Tsamis
    Psychology, Columbia University Irving Medical Center, New York, New York, United States
  • Aakriti Garg Shukla
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Qing Wang
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Noga Harizman
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • George A Cioffi
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Sitara Hanif Hirji
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • C. Gustavo De Moraes
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Xin Xin Xing None; Ari Leshno Schur Family Glaucoma Fellowship, Columbia University Department of Ophthalmology, Code F (Financial Support); Emmanouil Tsamis None; Aakriti Garg Shukla None; Qing Wang None; Noga Harizman None; George Cioffi None; Sitara Hirji None; C. Gustavo De Moraes Carl Zeiss, Novartis, Perfuse Therapeutics, Thea Pharma, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment); Jeffrey Liebmann AdvanceSight, Alcon, Inc., Allergan, Inc., Carl Zeiss Meditech, Genentech, Inc., Johnson & Johnson, Inc., ONL Therapeutics, Inc., Thea, Inc., Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2010. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      24-2 Visual Field Progression Rates Better Correlate with GCL than RNFL Rate of Change in Glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Xin Xin Xing, Ari Leshno, Emmanouil Tsamis, Aakriti Garg Shukla, Qing Wang, Noga Harizman, George A Cioffi, Sitara Hanif Hirji, C. Gustavo De Moraes, Jeffrey M Liebmann; 24-2 Visual Field Progression Rates Better Correlate with GCL than RNFL Rate of Change in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2010.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To assess the correlation between 24-2 visual field (VF) rates of progression (ROP24-2, dB/year), retinal nerve fiber layer (ROCRNFL, micron/year), and ganglion cell layer (GCL) rates of change (ROCGCL, micron/year).

Methods : A database of 78,298 VF and 49,559 macula and disc optical coherence tomography (OCT) scans from 11,234 eyes (6,495 patients) was generated from all Humphrey VF and Cirrus OCT (Carl Zeiss Meditech, Inc., Dublin, California, USA) of consecutive patients seen in a university-based glaucoma division between 02/01/2020 and 05/10/2022. For this study, we included all eyes with same-day reliable (false positive <15%) 24-2 VFs and OCT exams on at least five visits, and a minimum of 5 years follow-up. The global, superior, and inferior ROP24-2, ROCRNFL, and ROCGCL were obtained from the Forum Structure-Function Glaucoma Progression Analysis (Carl Zeiss Meditech, Dublin, California, USA). Pearson’s correlation coefficients (r) were calculated between all measurements.

Results : A total of 499 eyes (292 patients, aged [Mean±SD]: 66±11.3 years) met our inclusion criteria (follow-up duration: 7.7±2.1 years; visits: 6.2±1.9). Baseline global 24-2 MD, RNFL, and GCL were -3.9±4.9dB, 77.5±12.8 microns, and 69.4±11.1 microns, respectively. All correlations between ROP24-2, ROCRNFL, and ROCGCL were statistically significant (P<0.001). ROP24-2 had a stronger correlation with ROCGCL than with the ROCRNFL (r = 0.312 and 0.197 respectively). In a similar fashion, the superior ROP24-2 better correlated with the inferior ROCGCL than with the ROCRNFL of the inferior quadrant ROC (r = 0.238 vs 0.192), and the inferior ROP24-2 better correlated with the superior ROCGCL than with the ROCRNFL of the superior quadrant (r = 0.264 vs 0.217).

Conclusions : Glaucomatous visual field loss rates correlate better with the rates of GCL thinning than with the rates of RNFL thinning. GCL thinning may be a better marker of functional loss in glaucoma than RNFL.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept